pembrolizumab
merck
['keynote 189', 'pembro']
here are data from patients who completed the 35 planned cycles of pembrolizumab on keynote 189. in that group, rr 86% and mdor 58m with a 72% 3y os rate. note 40% alive without pd or subsequent therapy. looking forward to more details on this group. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him